openPR Logo
Press release

Sobera Capital’s portfolio company ACT Biotech sells oncology assets to Eddingpharm for up to $95 million

02-24-2014 04:25 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Sobera Capital GmbH

Sobera Capital’s portfolio company ACT Biotech sells

Berlin, February 19, 2014 - Sobera Capital’s portfolio company ACT Biotech, San Francisco, CA, sold its worldwide rights to three small molecule drug assets and other molecules to Chinese specialty pharmaceutical company Eddingpharm. The total consideration, including the upfront payment, can reach up to $95 million. Sobera Capital had acquired shares in ACT Biotech in February 2012 in course of a secondary direct transaction from Bayer AG.

Sobera Capital is a Berlin based independent secondary direct investor with a focus on venture capital and small-cap funds and assets in T.I.M.E.S, healthcare and selected other industries. Find more information at www.sobera-capital.com.

ACT Biotech is develops targeted, orally available cancer drugs targeting receptor tyrosine kinases. Find more information at www.actbiotech.com.

Eddingpharm is a specialty pharmaceutical Chinese company active in the four therapeutic areas clinical nutrition, oncology, antibiotics and respiratory system. Find more information at www.eddingpharm.com.

Sobera Capital GmbH
T +49 (0)30 57 70 88 - 372
F +49 (0)30 57 70 88 - 379
E sbeil@sobera-capital.com
W www.sobera-capital.com

Markgrafenstr. 33
D-10117 Berlin
Germany

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sobera Capital’s portfolio company ACT Biotech sells oncology assets to Eddingpharm for up to $95 million here

News-ID: 282407 • Views:

More Releases from Sobera Capital GmbH

Sobera Capital exits from cv cryptovision
Sobera Capital exits from cv cryptovision
Berlin, June 20, 2013 – The funds IMH Hannover Venture Capital, IMH Venture Capital Berlin and ACAM Holding, which are managed by Sobera Capital, sold their shares in security software company cv cryptovision GmbH. Acquirer was Bundesdruckerei GmbH which made a strategic investment into cryptovision and now holds 25% in the company. The funds managed by Sobera Capital had been invested in cryptovision since 2001. Sobera Capital is a Berlin based independent
Sobera Capital exits 4Care AG
Berlin, August 28, 2012 – Sobera Capital exits from its portfolio company 4Care AG through a sale of the shares held by the funds Berlin Capital Fund („BCF“) and TCF II in course of a management buy-out. BCF und TCF II had acquired 4Care AG (formerly Lenscare AG) in 2007 in a secondary transaction from Landesbank Berlin as well as from a co-shareholder. The company which owns brands like Lenscare,

More Releases for Biotech

Global Agricultural Biotech Market Analysis By Top Keyplayers - Agriland Biotech …
Market Overview The global agricultural biotech market, valued at USD 103.2 billion in 2023, is projected to reach USD 213.3 billion by 2031, growing at a CAGR of 9.5% from 2024 to 2031. Biotechnology in agriculture enhances productivity through genetic modification, producing crops with higher yields, pest and disease resistance, and better nutritional content. Recent advancements like CRISPR-Cas9 have revolutionized crop development, offering precise and efficient genetic enhancements. Emerging markets with
By Company Kingherbs Artemis NutriBotanica Kemin Vita Forte Alpspure Reindeer Bi …
Global Leading Market Research Publisher QYResearch announces the release of its lastest report "Global Acerola Cherry Extract Market Report, History and Forecast 2018-2029, Breakdown Data by Manufacturers, Key Regions, Types and Application". Based on historical analysis (2018-2022) and forecast calculations (2023-2029), this report provides a comprehensive analysis of the global Acerola Cherry Extract market, including market size, share, demand, industry development status, and forecasts for the next few years. Provides
Phycobiliproteins Market | Aim Grow Biotech Co., Ltd, Algapharma Biotech, Algene …
The global phycobiliproteins market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the phycobiliproteins market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth of the phycobiliproteins market.
Biotechnology-Based Chemical Market Size 2022: Kemin Europa, Clariant, JC Biotec …
Biotechnology-Based Chemical Market research report provides valuable insights by analyzing market trends and market scenarios over a defined period. It also presents manufacturing details like sales, volume, revenue, price, and gross margin. Furthermore, the import-export analysis, pricing analysis is also included in the report to understand the product demand and service. Finally, it also provides end-user application analysis, which delivers revenue, growth percentage of the product across the different applications.
Global Acetaminophen (Paracetamol) Market 2020 | Genesis Biotech, M.M. Pharma, A …
The Global Acetaminophen (Paracetamol) Market research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry validated market data. It also contains projections using a suitable set of assumptions and methodologies. The study provides company profiling, product picture and specifications, sales, market share and contact information of key manufacturers of Global Acetaminophen (Paracetamol) Market.The Key manufactures involved in this market
Global Ginkgetin Market 2019 - Hunan Nutramax, Shaanxi Pioneer Biotech, Xi'an So …
Ginkgetin is an extract from ginkgo biloba. Scope of the Report: Ginkgetin can dilate blood vessels, promote blood circulation, enhance immunity, and promote cerebral blood circulation and cell metabolism. The worldwide market for Ginkgetin is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017. This report focuses on the Ginkgetin in global market, especially in North